Large disparities in adoption of Alzheimer’s infusion therapy raise concerns about access

Adoption of lecanemab, a novel infusion treatment for Alzheimer’s disease (AD), has been disproportionately higher among patients who are male, white, from urban areas, and have higher socioeconomic status, new research suggests.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup